Genetic makeup may make radiation riskier for pediatric cancer patients

September 4, 2015 by Suzanne Leigh, University of California, San Francisco
Genetic makeup may make radiation riskier for pediatric cancer patients
This color washed CT scan shows graduated doses of radiation extending outwards from a brain tumor. The red central area is the high-dose region shaped to match tumor dimensions.

Genetic vulnerabilities associated with childhood cancers may make children undergoing radiation therapy more susceptible than adults to secondary cancers, according to novel insights from researchers at UC San Francisco.

Malignancies caused by radiation therapy are a major cause of mortality in childhood cancer patients and affect approximately 10 percent of long-term survivors, depending on diagnosis and prognosis. These secondary malignancies arise from DNA injury following radiation therapy and can be aggressive and challenging to treat.

While they can also occur in adults, experts are recognizing that they are more common in children.

In the study published Sept. 3, in Cell Reports, a team of international scientists, headed by senior author Jean Nakamura, MD, of UCSF, conducted an analysis of tumors in mice that were caused by both exposure to radiation and genetic mutations.

The researchers compared the prevalence of cancer in normal mice to those with a mutation in the Nf1 gene, which encodes a tumor-suppressing protein called neurofibromin. Children born with mutations in this gene have neurofibromatosis 1, a condition that predisposes them to tumors. In order to parallel the effects of on pediatric patients, young mice underwent focused radiation targeted to the abdominal wall. The dosing was similar to that received by patients.

After radiation the Nf1 mice harbored more tumors and had shorter lifespans than the normal mice.

"Comparing malignancies from two different genetic backgrounds helps us understand which genetic alterations are attributable to radiation and which genetic alterations are attributable to the germline mutations, those mutations present at birth," said Nakamura, associate professor of radiation oncology in the UCSF School of Medicine and a physician at UCSF Benioff Children's Hospital San Francisco.

The scientists sequenced malignancies from 19 mice, of which 15 tumors occurred in Nf1 mice and seven in normal mice, and identified common mutational signatures, irrespective of tumor type and genetic background.

The researchers looked at sarcomas, tumors usually arising from muscle or bone that are common secondary malignancies, and found that those of the Nf1 mice had fewer changes in DNA sequence than the normal mice. They also found that the cancers of the Nf1 mice were significantly more likely to have lost large segments of individual chromosomes compared to the normal mice. These findings indicate that germline mutations in Nf1 influence the numbers and types of found in tumors. Nakamura and her colleagues now are analyzing radiation-induced malignancies from pediatric patients for the mutation patterns they discovered in the mice.

"If we can identify whether are contributing to cancer development in , we have the potential to personalize cancer therapy and health management approaches to help these patients enjoy long-term health," said Nakamura. "Since individual patients have individual genetic profiles and different , we might be able to tailor medical care to integrate this information, rather than offering the same treatment to all children with the same diagnosis."

Nakamura hopes that the results of the study may enable scientists to understand the precise molecular steps and sources that contribute to cancer formation and block the process at the point at which it is easiest to manipulate.

"In the future, we may find that some of the mutational signatures that we identified reflect molecular deficiencies that we can prevent or correct," she said.

"One possibility is developing drugs to protect or reinforce genetic integrity during radiation exposure, as well as afterwards."

Explore further: Finding may aid diagnosis of learning disabilities linked to brain tumor syndrome​​

Related Stories

Finding may aid diagnosis of learning disabilities linked to brain tumor syndrome​​

July 22, 2015
New insight into one of the most common inherited causes of brain tumors may help physicians diagnose and treat the learning disabilities that often accompany the condition.

Targeting newly discovered pathway sensitizes tumors to radiation and chemotherapy

September 3, 2015
In some patients, aggressive cancers can become resistant to chemotherapy and radiation treatments. In a paper published in the journal Nature Communications, University of California, San Diego School of Medicine researchers ...

Radiation costs vary among Medicare patients with cancer

August 11, 2015
Cost of radiation therapy among Medicare patients varied most widely because of factors unrelated to a patient or that person's cancer, report University of California, San Diego School of Medicine researchers in the Journal ...

Researchers develop first genetic test to predict tumor sensitivity to radiation therapy

July 23, 2015
Recent advances in the understanding of cancer have led to more personalized therapies, such as drugs that target particular proteins and tests that analyze gene expression patterns in tumors to predict a patient's response ...

Study identifies 'major player' in skin cancer genes

July 27, 2015
A multidisciplinary team at Yale, led by Yale Cancer Center members, has defined a subgroup of genetic mutations that are present in a significant number of melanoma skin cancer cases. Their findings shed light on an important ...

Survivors of childhood cancer have high-risk of recurrent stroke

August 26, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood cancer have a high risk of suffering a stroke at a surprisingly young age.

Recommended for you

Probing RNA epigenetics and chromatin structures to predict drug resistance in leukemia

March 22, 2018
Drug resistance is a major obstacle to effective treatment for patients with cancer and leukemia. Epigenetic modifying drugs have been proven effective for some patients with hematologic malignancies, such as myelodysplastic ...

Gene-based test for urine detects, monitors bladder cancer

March 22, 2018
Researchers at The Johns Hopkins Kimmel Cancer Center have developed a test for urine, gathered during a routine procedure, to detect DNA mutations identified with urothelial cancers.

Researchers identify compound to prevent breast cancer cells from activating in brain

March 22, 2018
Researchers at Houston Methodist used computer modeling to find an existing investigational drug compound for leukemia patients to treat triple negative breast cancer once it spreads to the brain.

Could a pap test spot more than just cervical cancer?

March 22, 2018
Pap tests have helped drive down rates of cervical cancer, and a new study suggests they also could be used to detect other gynecologic cancers early.

Three-in-one molecule shows promise in helping certain breast cancer patients

March 22, 2018
A newly designed three-part molecule could be the one answer patients with a certain form of breast cancer are looking for, scientists report.

Researchers discover new anti-cancer protein

March 21, 2018
An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.